Streetbeat News

ICVX

Icosavax Inc

Employees

61

Industry

Biological Product (except Diagnostic) Manufacturing

icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. the company was founded on breakthrough computationally-designed virus like particle technology, exclusively licensed for a variety of infectious disease indications from the institute for protein design at the university of washington. icosavax is located in seattle.

Open

15.40

Mkt cap

769M

Volume

8.6M

High

15.44

P/E Ratio

-6.96

52-wk high

16.11

Low

15.28

Div yield

N/A

52-wk low

4.75

Guggenheim analyst Seamus Fernandez has downgraded Icosavax (NASDAQ:ICVX) from Buy to Neutral, indicating a change in the firm's outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 10:33 am

U.S. stocks closed higher with the Dow Jones gaining over 100 points. Materials shares rose by 0.5%, while energy shares fell by 1.7%. Johnson Controls reported Q4 results with sales growth of 2.7% Y/Y to $6.91 billion, missing estimates. Aditxt's shares surged 64% after agreeing to acquire Evofem Biosciences. C4 Therapeutics shares jumped 108% due to a collaboration agreement with Merck & Co. Icosavax shares increased 48% after AstraZeneca's acquisition announcement. Conversely, Achieve Life Sciences shares fell 42%, Oracle shares dropped 12%, and Green Giant shares declined 44%. Crude oil was down 4.1%, and gold slightly increased by 0.1%.

Portfolio Pulse from Avi Kapoor

December 12, 2023 | 7:23 pm

Johnson Controls International plc (NYSE:JCI) shares dropped over 6% due to weaker-than-expected quarterly results, with sales of $6.91 billion missing the $7.09 billion consensus and adjusted EPS of $1.05 below the $1.09 consensus. Other stocks experienced significant movements, with notable gainers including Aditxt, Inc. (ADTX), C4 Therapeutics, Inc. (CCCC), and Icosavax, Inc. (ICVX), among others. Losers included Achieve Life Sciences, Inc. (ACHV), Harbor Custom Development, Inc. (HCDI), and Oracle Corporation (ORCL), with various reasons such as FDA feedback, bankruptcy filing, and missed sales estimates, respectively.

Portfolio Pulse from Avi Kapoor

December 12, 2023 | 6:22 pm

During Tuesday's intraday session, several healthcare stocks experienced significant movements. C4 Therapeutics, Aditxt, Icosavax, Candel Therapeutics, IN8bio, and PAVmed saw their shares rise by 100.5%, 68.94%, 48.61%, 32.98%, 29.93%, and 29.33% respectively. Conversely, CareCloud, Achieve Life Sciences, Eterna Therapeutics, and Vapotherm witnessed their stock prices fall by 68.4%, 41.47%, 23.46%, and 20.01% respectively.

Portfolio Pulse from Benzinga Insights

December 12, 2023 | 5:31 pm

U.S. stocks saw gains with the Dow Jones rising over 100 points. Oracle Corporation reported mixed Q2 results with earnings beating estimates but revenue falling short. Aditxt, Inc. surged after agreeing to acquire Evofem Biosciences. C4 Therapeutics and Icosavax also saw stock increases due to a collaboration agreement with Merck and an acquisition by AstraZeneca, respectively. Conversely, Achieve Life Sciences, Harbor Custom Development, and Green Giant Inc. experienced significant stock declines.

Portfolio Pulse from Avi Kapoor

December 12, 2023 | 4:58 pm

Icosavax, Inc. (ICVX) shares surged following the announcement of its acquisition by AstraZeneca. Additionally, Icosavax released positive interim Phase 2 clinical trial results for IVX-A12, targeting RSV and hMPV in older adults.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 4:44 pm

Blue Bird Corporation (BLBD) reported Q4 earnings of 66 cents per share, surpassing expectations of 48 cents, with revenue of $302.96 million beating estimates of $290.11 million. The company also increased its FY24 revenue forecast, causing shares to rise 9.1% to $23.80. Other stocks making significant moves include Icosavax (ICVX) with a 47.1% jump after AstraZeneca's acquisition plans, and Eagle Bulk Shipping (EGLE) rising 9.2% following a merger announcement with Star Bulk. Various companies reported positive financial results or received favorable analyst ratings, contributing to their stock gains.

Portfolio Pulse from Avi Kapoor

December 12, 2023 | 3:13 pm

In Tuesday's pre-market session, several healthcare stocks experienced significant movements. C4 Therapeutics (CCCC) saw a 59.7% increase, while Candel Therapeutics (CADL) and Icosavax (ICVX) rose by 47.38% and 45.85%, respectively. AEON Biopharma (AEON), IN8bio (INAB), and Sonoma Pharmaceuticals (SNOA) also saw gains. Conversely, CareCloud (CCLDP), Achieve Life Sciences (ACHV), Assure Hldgs (IONM), Pasithea Therapeutics (KTTA), CareCloud (CCLDO), and Nexalin Technology (NXL) experienced declines, with CareCloud (CCLDP) dropping by 35.9%.

Portfolio Pulse from Benzinga Insights

December 12, 2023 | 1:07 pm

Icosavax, Inc. (NASDAQ:ICVX) shares surged approximately 45% in pre-market trading following AstraZeneca's announcement of plans to acquire Icosavax for up to $1.1 billion. Icosavax also reported positive interim Phase 2 results for its IVX-A12 vaccine candidate. Other stocks experiencing pre-market movements include gainers Bruush Oral Care Inc. (BRSH), Connect Biopharma Holdings Limited (CNTB), and losers Harbor Custom Development, Inc. (HCDI), which filed for Chapter 11 bankruptcy, and Oracle Corporation (ORCL), which reported mixed quarterly results.

Portfolio Pulse from Avi Kapoor

December 12, 2023 | 1:00 pm

AstraZeneca Plc (NASDAQ:AZN) is set to acquire Icosavax Inc (NASDAQ:ICVX) for over $800 million, offering $15.00 per share plus up to $5.00 in contingent value rights upon meeting certain milestones. The acquisition, expected to close in Q1 of 2024, will give AstraZeneca access to experimental vaccines for respiratory diseases. Icosavax's Phase 2 study of IVX-A12 showed promising results against RSV and hMPV. AstraZeneca's stock rose 1.56% to $64.49, while Icosavax's shares jumped 45.95% to $15.31 in premarket trading.

Portfolio Pulse from Vandana Singh

December 12, 2023 | 10:55 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.